Design optimization in nonlinear mixed effects models using cost functions: Application to a joint model of infliximab and methotrexate pharmacokinetics

Communications in Statistics - Theory and Methods

Volumn 38, Issue 18, 2009, Pages 3351-3368

  Retout, Sylvie ^a,b   Comets, Emmanuelle ^a,b   Bazzoli, Caroline ^a,b   Mentré, France ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Cost function; Design optimization; Fedorov Wynn algorithm; Fisher information matrix; Nonlinear mixed effects model; PFIM

Indexed keywords

DESIGN OPTIMIZATION; FEASIBLE DESIGN; FEDOROV-WYNN ALGORITHM; JOINT MODELS; MULTIPLE RESPONSE; NONLINEAR MIXED EFFECTS; NONLINEAR MIXED EFFECTS MODEL; OPTIMIZED DESIGNS; PFIM; PHARMACOKINETIC MODEL; RHEUMATOID ARTHRITIS;

COST FUNCTIONS; COSTS; DESIGN; DISTRIBUTED COMPUTER SYSTEMS; FISHER INFORMATION MATRIX; PHARMACOKINETICS;

OPTIMIZATION;

EID: 70349635972     PISSN: 03610926     EISSN: 1532415X     Source Type: Journal    
DOI: 10.1080/03610920902833511     Document Type: Article

References (32)

1. Al-Banna, M. K., Kelman, A. W., Whiting, B. (1990). Experimental design and efficient parameter estimation in population pharmacokinetics. J. Pharmacokin. Biopharm. 18(4):347-360.
2. Atkinson, A. C., Donev, A. N. (1992). Optimum experimental designs. In: Copas, J. B., Eagleson, G. K., Pierce, D. A., Schervish, M. J., eds. Oxford Statistical Science Series. Oxford: Clarendon Press.
3. Bazzoli, C., Retout, S., Mentré, F. (2007). Population design in nonlinear mixed effects multiple responses models: Extension of PFIM and evaluation by simulation with NONMEM and MONOLIX. Abstr 1176 [www.page-meeting.org/?abstract=1176], p. 16.
4. Beal, S. L., Sheiner, L. B. (1992). NONMEM users guides. In: Group, P., ed. NONMEM. San Francisco: University of California.
5. Fedorov, V. V. (1972). Theory of Optimal Experiments. New York: Academic Press.
6. Fedorov, V. V., Gagnon, R. C., Leonov, S. L. (2002). Design of experiments with unknown parameters in variance. Appl. Stochastic Models Bus. Industry 18(3):207-218.
7. Gagnon, R., Leonov, S. (2005). Optimal population designs for PK models with serial sampling. J. Biopharmaceut. Statist. 15(1):143-163.
8. Godfrey, C., Sweeney, K., Miller, K., Hamilton, R., Kremer, J. (1998). The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. Brit. J. Clin. Pharmacol. 46(4):369-376.
9. Gueorguieva, I., Aarons, L., Ogungbenro, K., Jorga, K. M., Rodgers, T., Rowland, M. (2006). Optimal design for multivariate response pharmacokinetic models. J. Pharmacokin. Pharmacodyn. 33(2):97-124.
10. Hooker, A., Vicini, P. (2005). Simultaneous population optimal design for pharmacokineticpharmacodynamic experiments. Amer. Assoc. Pharmaceut. Scientists 7(4):759-785.
11. Jonsson, E. N., Wade, J. R., Karlsson, M. O. (1996). Comparison of some practical sampling strategies for population pharmacokinetic studies. J. Pharmacokin. Biopharmaceut. 24(2):245-263.
12. Kavanaugh, A., St. Clair, E. W., McCune, W. J., Braakman, T., Lipsky, P. (2000). Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J. Rheumatol. 27(4):841-850.
13. Klotz, U., Teml, A., Schwab, M. (2007). Clinical pharmacokinetics and use of in.iximab. Clin. Pharmacokin. 46(8):645-660.
14. Kuhn, E., Lavielle, M. (2005). Maximum likelihood estimation in nonlinear mixed effects models. Computat. Statist. Data Anal. 49:1020-1038.
15. Louis, T. A. (1982). Finding the observed information matrix when using the EM algorithm. J. Roy. Statis. Soc. Ser. B (Methodol.) 44(2):226-233.
16. Maini, R. N., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Davis, D., Macfarlane, J. D., Antoni, C., Leeb, B., Elliott, M. J., Woody, J. N., Schaible, T. F., Feldman, M. (1998). Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41(9):1552-1563.
17. Mallet, A. (1986). A maximum likelihood estimation method for random coefficient regression models. Biometrika 73(3):645-656.
18. Mentré, F., Mallet, A., Baccar, D. (1997). Optimal design in random-effects regression models. Biometrika 84(2):429-442.
19. Panhard, X., Goujard, C., Legrand, M., Taburet, A. M., Diquet, B., Mentre, F. (2005). Population pharmacokinetic analysis for nel.navir and its metabolite M8 in virologically controlled HIV-infected patients on HAART. Brit. J. Clin. Pharmacol. 60(4):390-403.
20. Pillai, G. C., Mentré, F., Steimer, J. L. (2005). Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science. J. Pharmacokin. Pharmacodyn. 32(2):161-183.
21. Pinheiro, J. C., Bates, D. M. (1995). Approximations to the log-likelihood function in the nonlinear mixed-effects model. J. Computat. Graph. Statist. 4(1):12-35.
22. Retout, S., Mentré, F. (2003a). Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics. J. Biopharmaceut. Statist. 13(2):209-227.
23. Retout, S., Mentré, F. (2003b). Optimisation of individual and population designs using Splus. J. Pharmacokin. Pharmacodyn. 30(6):417-443.
24. Retout, S., Duffull, S., Mentré, F. (2001). Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs. Comput. Meth. Programs Biomed. 65(2):141-151.
25. Retout, S., Mentré, F., Bruno, R. (2002). Fisher information matrix for non-linear mixed-effects models: Evaluation and application for optimal design of enoxaparin population pharmacokinetics. Statist. Med. 21(18):2623-2639.
26. Retout, S., Comets, E., Samson, A., Mentré, F. (2007). Design in nonlinear mixed effects models: Optimization using the Fedorov-Wynn algorithm and power of the Wald test for binary covariates. Statis. Med. 26(28):5162-5179.
27. Samson, A., Lavielle, M., Mentré, F. (2006). Extension of the SAEM algorithm to leftcensored data in nonlinear mixed-effects model: application to HIV dynamics model. Computat. Statist. Data Anal. 51:1562-1574.
28. Sheiner, L. B., Rosenberg, B., Melmon, K. L. (1972). Modelling of individual pharmacokinetics for computer-aided drug dosage. Compu. Biomed. Res. 5(5):411-459.
29. St Clair, E. W., Wagner, C. L., Fasanmade, A. A., Wang, B., Schaible, T., Kavanaugh, A., et al. (2002). The relationship of serum in.iximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46(6):1451-1459.
30. van Breukelen, G. J. P., Candel, M. J. J. M., Berger, M. P. F. (2008). Relative efficiency of unequal cluster sizes for variance component estimation in cluster randomized and multicentre trials. Statist. Meth. Med. Res. 17(4):439-458.
31. Walter, E., Pronzato, L. (1997). Identification of parametric models from experimental data. In: Dickinson, B. W., Fettweis, A., Massay, J. L., Modestino, J. W., Sontag, E. D., Thoma, M., eds. Communications and Control Engineering. New York: Springer-Verlag.
32. Wynn, H. P. (1972). Results in the construction of D-optimum experimental designs. J. Roy. Statist. Soc. B 34:133-147.